Comparision of the efficacy of two treatment methods including baicalin mucoadhesive paste with betamethasone mouthwash and betamethasone mouthwash alone in patients with oral lichen planus

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241114063707N1

Enrollment

Registered

2024-11-25

Start date

2024-12-20

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral lichen planus. Other lichen planus

Interventions

Intervention 1: Intervention group: Mucoadhesive baicalin with betamethasone mouthwash in patients with oral lichen planus. First, the plastibase base is prepared. This base is made of polyethylene an

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with definite diagnosis of oral lichen planus based on clinical and histopathological findings Patients with at least one visible and measurable ulcerative or atrophic or reticular lichen planus lesion. Adult patients (over 18 years old) Patients who do not receive immunosuppressive drugs Patients without underlying disease Patients with complete records including clinical and demographic information

Exclusion criteria

Exclusion criteria: Smoking, alcohol consumption, caffeine The presence of uncontrolled diabetes, hypertension and other underlying diseases that hinder participation in the study Immune system suppression Presence of other simultaneous skin or mucosal lesions Received treatment for oral lichen planus in the last 12 weeks Patients with oral candidiasis Viral infections Lesions showing any dysplastic changes. Unwillingness to participate in the study

Design outcomes

Primary

Measure	Time frame
Clinical score based on Thongprasom scale. Timepoint: At the beginning of the intervention, 2 weeks later, 4 weeks later. Method of measurement: The clinical score will be based on Thongprasom's scale : Grade 0 = no lesion / normal mucosaGrade 1 = white striae / no erythematous areaGrade 2 = white striae with an atrophic area equal to or less than 1 cm2Grade 3 = white striae with an atrophic area greater than 1 cm2Grade 4 = white striae with an erogenous area equal to or less than 1 cm2Grade 5 = white striae with an erogenous zone greater than 1 cm2.;Pain based on Visual Analogue Scale(VAS). Timepoint: At the beginning of the intervention, 2 weeks later, 4 weeks later. Method of measurement: Pain will be evaluated using the Visual Analogue Scale including a 10 cm horizontal line (0 = no pain, 10 = the most severe pain experienced).	—

Measure

Time frame

Clinical score based on Thongprasom scale. Timepoint: At the beginning of the intervention, 2 weeks later, 4 weeks later. Method of measurement: The clinical score will be based on Thongprasom's scale : Grade 0 = no lesion / normal mucosaGrade 1 = white striae / no erythematous areaGrade 2 = white striae with an atrophic area equal to or less than 1 cm2Grade 3 = white striae with an atrophic area greater than 1 cm2Grade 4 = white striae with an erogenous area equal to or less than 1 cm2Grade 5 = white striae with an erogenous zone greater than 1 cm2.;Pain based on Visual Analogue Scale(VAS). Timepoint: At the beginning of the intervention, 2 weeks later, 4 weeks later. Method of measurement: Pain will be evaluated using the Visual Analogue Scale including a 10 cm horizontal line (0 = no pain, 10 = the most severe pain experienced).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Kouhsoltani

Tabriz University of Medical Sciences

mkoohsoltani@yahoo.com+98 41 3334 0310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026